The protective effect of fenofibrate against TNF-α-induced CD40 expression through SIRT1-mediated deacetylation of NF-κB in endothelial cells

Inflammation

Volumn 37, Issue 1, 2014, Pages 177-185

  Wang, Weirong ^a   Bai, Ling ^a   Qiao, Hu ^a   Li, Yanxiang ^a   Yang, Lina ^a   Zhang, Jiye ^a   Lin, Rong ^a   Ren, Feng ^a   Zhang, Jianfeng ^a   Ji, Meixi ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

CD40; endothelial cells; fenofibrate; NF B; SIRT1

Indexed keywords

CD40 ANTIGEN; FENOFIBRATE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; NICOTINAMIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PYRROLIDINE DITHIOCARBAMATE; SIRTINOL; SIRTUIN 1; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN EXPRESSION; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; DEACETYLATION; DRUG EFFECT; ENDOTHELIUM CELL; GENE SEQUENCE; HUMAN; HUMAN CELL; HYPERCHOLESTEROLEMIA; INFLAMMATION; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RNA INTERFERENCE; UMBILICAL VEIN ENDOTHELIAL CELL; WESTERN BLOTTING;

ACETYLATION; ANTIGENS, CD40; ANTIOXIDANTS; BENZAMIDES; CELLS, CULTURED; FENOFIBRATE; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; HYPOLIPIDEMIC AGENTS; INFLAMMATION; NAPHTHOLS; NIACINAMIDE; OXAZOLES; PPAR ALPHA; PYRROLIDINES; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SIRTUIN 1; THIOCARBAMATES; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR-ALPHA; TYROSINE; UP-REGULATION;

EID: 84900350449     PISSN: 03603997     EISSN: 15732576     Source Type: Journal    
DOI: 10.1007/s10753-013-9728-6     Document Type: Article

References (40)

1. Madej, A., B. Okopien, J. Kowalski, M. Zielinski, J. Wysocki, B. Szygula, Z. Kalina, and Z.S. Herman. 1998. Effects of fenofibrate on plasma cytokine concentrations in patients with atherosclerosis and hyperlipoproteinemia IIb. International Journal of Clinical Pharmacology and Therapeutics 36: 345-349. (Pubitemid 28271555)
2. Keech, A., R.J. Simes, P. Barter, J. Best, R. Scott, M.R. Taskinen, P. Forder, A. Pillai, T. Davis, P. Glasziou, P. Drury, Y.A. Kesaniemi, D. Sullivan, D. Hunt, P. Colman, M. d'Emden, M. Whiting, C. Ehnholm, and M. Laakso. 2005. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): Randomised controlled trial. Lancet 366: 1849-1861.
3. Fruchart, J.C., P. Duriez, and B. Staels. 1999. Peroxisome proliferator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis. Current Opinion in Lipidology 10: 245-257. (Pubitemid 29405915)
4. Duez, H., Y.S. Chao, M. Hernandez, G. Torpier, P. Poulain, S. Mundt, Z. Mallat, E. Teissier, C.A. Burton, A. Tedgui, J.C. Fruchart, C. Fievet, S.D. Wright, and B. Staels. 2002. Reduction of atherosclerosis by the peroxisome proliferator-activated receptor alpha agonist fenofibrate in mice. Journal of Biological Chemistry 277: 48051-48057. (Pubitemid 35470751)
5. Lin, R., J.T. Liu, W.J. Gan, W.R. Wang, C.J. Han, and Z.Y. Fang. 2006. Fenofibrate inhibits tumor necrosis factor-alpha-induced expression of CD40 and matrix metalloproteinase in human vascular endothelial cells. Journal of Southern Medical University 26: 1383-1387.
6. Rizvi, M., D. Pathak, J.E. Freedman, and S. Chakrabarti. 2008. CD40-CD40 ligand interactions in oxidative stress, inflammation and vascular disease. Trends in Molecular Medicine 14: 530-538.
7. Haigis, M.C., and L.P. Guarente. 2006. Mammalian sirtuins-emerging roles in physiology, aging, and calorie restriction. Genes & Development 20: 2913-2921. (Pubitemid 44771725)
8. Stein, S., and C.M. Matter. 2011. Protective roles of SIRT1 in atherosclerosis. Cell Cycle 10: 640-647.
9. Csiszar, A., N. Labinskyy, A. Podlutsky, P.M. Kaminski, M.S. Wolin, C.H. Zhang, P. Mukhopadhyay, P. Pacher, F.R. Hu, R. de Cabo, P. Ballabh, and Z. Ungvari. 2008. Vasoprotective effects of resveratrol and SIRT1: Attenuation of cigarette smoke-induced oxidative stress and proinflammatory phenotypic alterations. American Journal of Physiology-Heart and Circulatory Physiology 294: H2721-H2735.
10. Csiszar, A., N. Labinskyy, R. Jimenez, J.T. Pinto, P. Ballabh, G. Losonczy, K.J. Pearson, R. de Cabo, and Z. Ungvari. 2009. Antioxidative and anti-inflammatory vasoprotective effects of caloric restriction in aging: Role of circulating factors and SIRT1. Mechanisms of Ageing and Development 130: 518-527.
11. Stein, S., N. Schafer, A. Breitenstein, C. Besler, S. Winnik, C. Lohmann, K. Heinrich, C.E. Brokopp, C. Handschin, U. Landmesser, F.C. Tanner, T.F. Luscher, and C.M. Matter. 2010. SIRT1 reduces endothelial activation without affecting vascular function in ApoE-/-mice. Aging (Albany NY) 2: 353-360.
12. Salminen, A., A. Kauppinen, T. Suuronen, and K. Kaarniranta. 2008. Sirt1 longevity factor suppresses nf-kappa b-driven immune responses: Regulation of aging via nf-kappa b acetylation? Bioessays 30: 939-942.
13. Lin, R., J.T. Liu, N. Peng, G.D. Yang, W.J. Gan, and W.R. Wang. 2005. Lovastatin reduces nuclear factor kappa b activation induced by C-reactive protein in human vascular endothelial cells. Biological & Pharmaceutical Bulletin 28: 1630-1634. (Pubitemid 41324122)
14. Grozinger, C.M., E.D. Chao, H.E. Blackwell, D. Moazed, and S.L. Schreiber. 2001. Identification of a class of small molecule inhibitors of the sirtuin family of NAD-dependent deacetylases by phenotypic screening. Journal of Biological Chemistry 276: 38837-38843.
15. Bitterman, K.J., R.M. Andersonm, H.Y. Cohen, M. Latorre-Esteves, and D.A. Sinclair. 2002. Inhibition of silencing and accelerated aging by nicotinamide, a putative negative regulator of yeast sir2 and human SIRT1. Journal of Biological Chemistry 277: 45099-45107. (Pubitemid 36159111)
16. Yang, L.N., J.Y. Zhang, C.F. Yan, J. Zhou, R. Lin, Q.Q. Lin, W.R. Wang, K.F. Zhang, G.D. Yang, X.L. Bian, and A.G. Zeng. 2012. SIRT1 regulates CD40 expression induced by TNF-α via NF-κB pathway in endothelial cells. Cellular Physiology and Biochemistry 30: 1287-1298.
17. Xu, H.E., T.B. Stanley, V.G. Montana, M.H. Lambert, B.G. Shearer, J.E. Cobb, D.D. McKee, C.M. Galardi, K.D. Plunket, R.T. Nolte, D.J. Parks, J.T. Moore, S.A. Kliewer, T.M. Willson, and J.B. Stimmel. 2002. Structural basis for antagonist-mediated recruitment of nuclear co-repressors by PPAR alpha. Nature 415: 813-817. (Pubitemid 34150506)
18. Sung, B., S. Park, B.P. Yu, and H.Y. Chung. 2004. Modulation of PPAR in aging, inflammation, and calorie restriction. Journals of Gerontology Series A: Biological Sciences and Medical Sciences 59: 997-1006. (Pubitemid 39441788)
19. Barroso, E., E. Eyre, X. Palomer, and M. Vazquez-Carrera. 2011. The peroxisome proliferator-activated receptor beta/delta (PPAR beta/delta) agonist GW501516 prevents TNF-alpha-induced NF-kappa B activation in human HaCaT cells by reducing p65 acetylation through AMPK and SIRT1. Biochemical Pharmacology 81: 534-543.
20. Xue, B.Z., Z.G. Yang, X.F. Wang, and H. Shi. 2012. Omega-3 Polyunsaturated Fatty Acids Antagonize Macrophage Inflammation via Activation of AMPK/SIRT1 Pathway. PLoS ONE 7: 1-6.
21. Lin, R., J.T. Liu, W.J. Gan, and G.D. Yang. 2004. C-reactive protein-induced expression of CD40-CD40L and the effect of lovastatin and fenofibrate on it in human vascular endothelial cells. Biological & Pharmaceutical Bulletin 27: 1537-1543. (Pubitemid 41701635)
22. Fang, Z.Y., R. Lin, B.X. Yuan, Y. Liu, and H. Zhang. 2007. Tanshinone IIA inhibits atherosclerotic plaque formation by downregulating MMP-2 and MMP-9 expression in rabbits fed a high-fat diet. Life Sciences 81: 1339-1345. (Pubitemid 47599531)
23. Gocmen, A.Y., D. Burgucu, and S. Gumuslu. 2011. Effect of resveratrol on platelet activation in hypercholesterolemic rats: CD40-CD40L system as a potentialtarget. Applied Physiology Nutrition and Metabolism-Physiologie Appliquee Nutrition et Metabolisme 36: 323-330.
24. Cheng, H.L., R. Mostoslavsky, S. Saito, J.P. Manis, Y.S. Gu, P. Patel, R. Bronson, E. Appella, F.W. Alt, and K.F. Chua. 2003. Developmental defects and p53 hyperacetylation in Sir2 homolog (SIRT1)-deficient mice. Proceedings of the National Academy of Sciences of the United States of the United States of America 100: 10794-10799. (Pubitemid 37140107)
25. Yeung, F., J.E. Hoberg, C.S. Ramsey, M.D. Keller, D.R. Jones, R.A. Frye, and M.W. Mayo. 2004. Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO Journal 23: 2369-2380. (Pubitemid 38954844)
26. Marx, N., G.K. Sukhova, T. Collins, P. Libby, and J. Plutzky. 1999. PPAR alpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation 99: 3125-3131. (Pubitemid 29289077)
27. Yang, T.L., M.F. Chen, B.L. Luo, Q.Y. Xie, J.L. Jiang, and Y.J. Li. 2005. Fenofibrate decreases asymmetric dimethylarginine level in cultured endothelial cells by inhibiting NF-κB activity. Naunyn-Schmiedeberg's Archives of Pharmacology 371: 401-407.
28. Zhang, Y.F., Y. Xiao, J. Yang, Y.N. Wu, X.L. Wang, R. Zou, M. Zhang, Q.Y. Liu, N. Guo, X.Q. Luo, X.Q. Dong, and X.Q. Yu. 2009. Rosiglitazone down-regulates lipopolysaccharide-induced expression of CD40 and intercellular adhesion molecule 1 in rat peritoneal mesothelial cells through a NF-kappaB dependent mechanism. Chinese Journal of Nephrology 25: 430-436.
29. Karin, M., and Y. Ben-Neriah. 2000. Phosphorylation meets ubiquitination: The control of NF-kappa B activity. Annual Review of Immunology 18: 621.
30. Tak, P.P., and G.S. Firestein. 2001. NF-kappaB: A key role in inflammatory diseases. Journal of Clinical Investigation 107: 7-11. (Pubitemid 32047405)
31. Chen, L.F., Y.J. Mu, and W.C. Greene. 2002. Acetylation of ReIA at discrete sites regulates distinct nuclear functions of NF-kappa B. EMBO Journal 21: 6539-6548. (Pubitemid 35448431)
32. Kiernan, R., V. Bres, R.W.M. Ng, M.P. Coudart, S. El Messaoudi, C. Sardet, D.Y. Jin, S. Emiliani, and M. Benkirane. 2003. Post-activation turn-off of NF-kappa B-dependent transcription is regulated by acetylation of p65. Journal of Biological Chemistry 278: 2758-2766. (Pubitemid 36801357)
33. Viatour, P., S. Legrand-Poels, C. van Lint, M. Warnier, M.P. Merville, J. Gielen, J. Piette, V. Bours, and A. Chariot. 2003. Cytoplasmic I kappa B alpha increases NF-kappa B-independent transcription through binding to histone deacetylase (HDAC)1 and HDAC3. Journal of Biological Chemistry 278: 46541-46548. (Pubitemid 37452227)
34. Seong, A.R., J.Y. Yoo, K. Choi, M.H. Lee, Y.H. Lee, J. Lee, W. Jun, S. Kim, and H.G. Yoon. 2011. Delphinidin, a specific inhibitor of histone acetyltransferase, suppresses inflammatory signaling via prevention of NF-kappa B acetylation in fibroblast-like synoviocyte MH7A cells. Biochemical and Biophysical Research Communications 410: 581-586.
35. Lei, M., J.G. Wang, D.M. Xiao, M. Fan, D.P. Wang, J.Y. Xiong, Y. Chen, Y. Ding, and S.L. Liu. 2012. Resveratrol inhibits interleukin 1 beta-mediated inducible nitric oxide synthase expression in articular chondrocytes by activating SIRT1 and thereby suppressing nuclear factor-kappa B activity. European Journal of Pharmacology 674: 73-79.
36. Okopien, B., R. Krysiak, and Z.S. Herman. 2006. Effects of short-term fenofibrate treatment on circulating markers of inflammation and hemostasis in patients with impaired glucose tolerance. Journal of Clinical Endocrinology & Metabolism 91: 1770-1778.
37. Delerive, P., J. Fruchart, and B. Staels. 2001. Peroxisome proliferator-activated receptors in inflammation control. Journal of Endocrinology 169: 453-459. (Pubitemid 32536978)
38. Fokko, Z.A., and J. Plutzky. 2007. PPAR alpha in atherosclerosis and inflammation. Biochimica et Biophysica Acta-Molecular and Cell Biology of Lipids 1771: 972-982.
39. Tomizawa, A., Y. Hattori, T. Inoue, S. Hattori, and K. Kasai. 2011. Fenofibrate suppresses microvascular inflammation and apoptosis through adenosine monophosphate-activated protein kinase activation. Metabolism-Clinical and Experimental 60: 513-522.
40. Planavila, A., R. Iglesias, M. Giralt, and F. Villarroya. 2011. Sirt1 acts in association with PPAR alpha to protect the heart from hypertrophy, metabolic dysregulation, and inflammation. Cardiovascular Research 90: 276-284.